ArticleBioengineered
Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.
Article in Bioengineered. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Enabling technologies for in situ biomanufacturing using probiotic yeast.Advanced drug delivery reviews · 2025Review
- Systematic Engineering for Efficient Uric Acid-Degrading Activity in Probiotic YeastACS synthetic biology · 2025Article
- Heterologous Expression of the Antiviral Lectin Griffithsin in ProbioticMicroorganisms · 2024Article
- Novel Insights in the Application of Probiotic YeastFoods (Basel, Switzerland) · 2024Review
- Ingesting yeast extract causes excitation of neurogenic and myogenic colonic motor patterns in the rat.Journal of cellular and molecular medicine · 2024Article
- Evaluation of nutritional and physicochemical characteristics of soy yogurt by Lactobacillus plantarum KU985432 and Saccharomyces boulardii CNCMI-745.Scientific reports · 2023Article
- Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.Microbial cell factories · 2021Article
- Ferulated Pectins and Ferulated Arabinoxylans Mixed Gel forMolecules (Basel, Switzerland) · 2021Article
- Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.Probiotics and antimicrobial proteins · 2021Article
- A probiotic yeast-based immunotherapy againstScience translational medicine · 2020Article
- A Mutation inApplied and environmental microbiology · 2018Article
- Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii.Scientific reports · 2017Article
- Metabolic Engineering of Probiotic Saccharomyces boulardii.Applied and environmental microbiology · 2016Article
- Prospects for immunotherapy and vaccines against Cryptosporidium.Human vaccines & immunotherapeutics · 2014Review
- Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saccharomyces boulardii (S. boulardii) is a probiotic yeast related to Saccharomyces cerevisiae (S. cerevisiae) but with distinct genetic, taxonomic and metabolic properties. S. cerevisiae has been used extensively in biotechnological applications. Currently, many strains are available, and multiple genetic tools have been developed, which allow the expression of several exogenous proteins of interest with applications in the fields of medicine, biofuels, the food industry, and scientific research, among others. Although S. boulardii has been widely studied due to its probiotic properties against several gastrointestinal tract disorders, very few studies addressed the use of this yeast as a vector for expression of foreign genes of interest with biotechnological applications. Here we show that, despite the similarity of the two yeasts, not all genetic tools used in S. cerevisiae can be applied in S. boulardii. While transformation of the latter could be obtained using a commercial kit developed for the former, consequent screening of successful transformants had to be optimized. We also show that several genes frequently used in genetic manipulation of S. cerevisiae (e.g., promoters and resistance markers) are present in S. boulardii. Sequencing revealed a high rate of homology (> 96%) between the orthologs of the two yeasts. However, we also observed some of them are not eligible to be targeted for transformation of S. boulardii. This work has important applications toward the potential of this probiotic yeast as an expression system for genes of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.